IN8bio’s Promising T Cell Engager Program and Strategic Developments Earns Buy Rating

Analyst Soumit Roy of JonesTrading maintained a Buy rating on IN8bio (INAB – Research Report), retaining the price target of $1.20.

Soumit Roy has given his Buy rating due to a combination of factors including promising preclinical data and strategic development plans. IN8bio’s gamma-delta T cell engager program, particularly the INB-619 targeting CD19, has shown potential in autoimmune diseases through effective B-cell depletion and sustained expansion of gamma-delta T cells.
Furthermore, the company’s focus on its leukemia program, with anticipated data updates, adds to the positive outlook. The unique mechanism of IN8bio’s TCEs, which avoids excessive inflammatory responses common in traditional therapies, further supports the Buy rating. The potential for partnerships and collaborations in advancing these programs also contributes to the favorable assessment.